Buprenorphine following ketamine treatment enhances anti‐suicidal effects
Patients with major depressive disorder (MDD) who received 4 weeks of buprenorphine treatment following a single infusion of ketamine experienced a significant reduction in suicidal ideation compared with ketamine plus placebo, a randomized, double‐blind trial has found. No serious treatment‐related adverse events were reported. Study results were published online May 19, 2026 in the American Journal of Psychiatry .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2026-08-03
- DOI
- https://doi.org/10.1002/pu.31484
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00